Myriad Genetics (MYGN) Cash from Investing Activities (2009 - 2026)

Myriad Genetics has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$6.5 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 21.69% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$25.6 million (down 95.42% YoY), while the FY2025 annual figure was -$27.4 million, down 130.25% from the prior year.
• Cash from Investing Activities slipped to -$6.5 million in Q1 2026, from -$6.0 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for MYGN reached as high as $34.6 million in Q1 2023 and fell as low as -$41.3 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is -$6.4 million (2024), against an average of -$5.4 million.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 1190.91% — and 2024, when it surged 400.0%.
• A 5-year view of Cash from Investing Activities shows it stood at -$35.6 million in 2022, then surged by 66.29% to -$12.0 million in 2023, then jumped by 50.83% to -$5.9 million in 2024, then decreased by 1.69% to -$6.0 million in 2025, then declined by 8.33% to -$6.5 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$6.5 million, -$6.0 million, and -$6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.